<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Commercialization of Stem Cells</title>
	<atom:link href="http://www.xconomy.com/boston/2008/01/25/commercialization-of-stem-cells/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2008/01/25/commercialization-of-stem-cells/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 01:49:51 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Diane Biederbeck</title>
		<link>http://www.xconomy.com/boston/2008/01/25/commercialization-of-stem-cells/comment-page-1/#comment-6859</link>
		<dc:creator>Diane Biederbeck</dc:creator>
		<pubDate>Sat, 26 Jan 2008 14:13:14 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/2008/01/25/commercialization-of-stem-cells/#comment-6859</guid>
		<description>1. Autologous stem cells have been proven safe in anecdotal and clinical studies for years in many parts of the world...There needs to be a differentiation between chemically based and/or donor therapies from patient derived miminally manipulated cell therapies within the FDA.  We need to lift the regulatory burdens that are unnecessary in autologous stem cell products.

2.  All chemically based therapeutic compounds should first be tested on human cells preclinical, rather than immune suppressed animal testing, before use on live human patients.</description>
		<content:encoded><![CDATA[<p>1. Autologous stem cells have been proven safe in anecdotal and clinical studies for years in many parts of the world…There needs to be a differentiation between chemically based and/or donor therapies from patient derived miminally manipulated cell therapies within the FDA.  We need to lift the regulatory burdens that are unnecessary in autologous stem cell products.</p>
<p>2.  All chemically based therapeutic compounds should first be tested on human cells preclinical, rather than immune suppressed animal testing, before use on live human patients.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

